Horizon confirms buyer interest from Amgen, Janssen, Sanofi
The company, which Genmab has partnered with over its highly profitable eye drug Tepezza, is potentially being targeted for acquisition by a number of big pharma firms.
by marketwire, translated by daniel pedersen
Pharmaceutical firm Horizon Therapeutics is struggling, and on Tuesday confirmed buyer interesting of a string of the industry’s biggest companies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Amgen hails cost-saving effect of biosimilars
For subscribers
Horizon's Genmab drug gets blockbuster status
For subscribers
